Ovid Application Error
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial. Wen, Bingbing 1; Zhang, Xiaohan 1; Chen, Shiyu 1; Fan, Jingchao 1; Yang, Sitian 1; Cai, Yun 1; Wang, Pengcheng 1; Zhang, Qiaoxia 1; Gu, Qingli 1; Du, Xin 1 [Article] Hematological Oncology. 40(4):777-786, October 2022.
(Format: HTML, PDF)